A rush of biotechs entered the public market Thursday morning, led by a $102 million upsized initial public offering (IPO) by Avalanche Biotechnologies Inc., which priced at the high end of its previously raised range, selling 6 million shares at $17 apiece and receiving an enthusiastic welcome on Nasdaq.